Poster Session B
Monday, September 19, 2016
12:30 p.m.–3:00 p.m.
Bayshore 4–7

B01, PR05 Using medical informatics to evaluate the risk of colorectal cancer in patients with clinically diagnosed sessile serrated polyps. Andrea Burnett-Hartman, Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, United States.

B03 Blood test of metastatic predisposition in colon cancer. Peter Geck, Tufts University School of Medicine, Boston, MA, United States.

B04 Protein and glycomic plasma markers for early detection of colon adenoma and cancer. Paul Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

B05 The RNA-binding protein HuR enhances exosome secretion in colorectal cancer. Ranjan Preet, Kansas University Medical Center, Kansas City, KS, United States.

B06 Cathepsin B expression in colorectal cancer in Middle East population: Potential value as a tumor biomarker for late stages. Maha Abdulla, King Saud University, Riyadh, Saudi Arabia.

B07 Molecular characterization of colorectal cancer in West Africans. Abiola Ibraheem, University of Chicago, Chicago, IL, United States.

B08 Potential biomarkers for colorectal cancer diagnosis and prognosis. Hicham Mansour, Translational Genomics Research Group, OLMAN-RL, FPN, University Mohamed 1st, Oujda, Morocco.

B09 Molecular phenotyping of colorectal tumors in clinical practice: Assignment of extended prognostic subtypes by direct testing of endoscopic specimens. Marek Minarik, Centre for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic.

B10 Clinicopathological characteristics and prevalence of KRAS and BRAF mutation in Korean patients with colorectal cancer. Kim Myung Jo, Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of.

B11 Asthma and risk of colorectal cancer according to tumor immunity and molecular subtypes. Yin Cao, Massachusetts General Hospital, Boston, MA, United States.

B12 Immune checkpoint blockade to improve T cell infiltration and function in colorectal cancer. Krithika Kodumudi, Moffitt Cancer Center, Tampa, FL, United States.


B14 TP53 synthetic lethal targets in colon cancer. Phillip Buckhaults, University of South Carolina, Columbia, SC, United States.

Poster Session B
Monday, September 19, 2016
12:30 p.m.–3:00 p.m.
Bayshore 4–7

B16 Activation of NRF2 and adaptive resistance to chemotherapy. Sarah Clinton, University of South Carolina, Columbia, SC, United States.

B17 CCAT1 is an enhancer RNA that predict BET inhibitor response in colorectal cancer. Ron Firestein, Hudson Institute of Medical Research, Clayton, Vic, Australia.

B18, PR09 Targeting the MYC-WDR5 nexus in colorectal cancer. Audra Foshage, Vanderbilt University, Nashville, TN, United States.

B19 Disruption of energy homeostasis as an approach to block the proliferation of colon carcinomatosis. Manuela Gariboldi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

B20 Fractional laser exposure can stimulate systemic anti-tumor immune response. Masayoshi Kawakubo, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

B21 PDE10A overexpression in colon cancer cells and tumors relative to normal colonocytes and colon mucosa. Ashley Lindsey, University of South Alabama, Mobile, AL, United States.

B22 Inhibition of the coding region determinant-binding protein (CRD-BP) to sensitize colorectal cancer cells to drug. Felicite Noubissi, Jackson State University, Jackson, MS, United States.

B23 DC070-547, a novel Ras inhibitor, potently and selectivity inhibits colon tumor growth in vitro and in vivo. Veronica Ramirez-Alcantara, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, United States.

B24 The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA—Selected case studies. Lucie Benesova, Centre for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic.

B25 Black-white differences in colorectal cancer screening and incidence over time by age and sex. Stacey Fedewa, Emory University, American Cancer Society, Atlanta, GA, United States.

B26 Baseline serum albumin as a prognostic actor in patients with stage I and II colon adenocarcinoma. Luis Onate-Ocana, Instituto Nacional de Cancerología, Mexico, Mexico.

B27 Serum uric acid levels as a prognostic factor in male patients with non-metastatic colorectal cancer. Shin Rumi, Seoul National University Boramae Medical Center, Seoul, Dongjak-Gu, Korea, Republic Of.

B28 Distinct patient and tumor characteristics of the consensus molecular subtypes of colorectal cancer. Jennifer Davis, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B30 Genomic approaches identify genetic changes contributing to colorectal adenoma to carcinoma progression. Ling-Hui Li, Academia Sinica, Taipei, Taiwan.

B31 Generation of a chimeric Egfr protein reporter mouse to uncover novel aspects of EGFR expression and trafficking in vivo. Wei Li, Vanderbilt University Medical Center, Nashville, TN, United States.

B32 A new 3D culture system identifies disease-relevant genes in colorectal cancer. Bhuminder Singh, Vanderbilt University School of Medicine, Nashville, TN, United States.

B33 Clustering of lateral Integrin Alpha 5 restores epithelial polarity in invasive colorectal cancer cells. Alina Starchenko, Vanderbilt University School of Medicine, Nashville, TN, United States.

B34 Total and free vitamin D, vitamin D binding protein, and colorectal cancer risk in the Southern Community Cohort Study. Shaneda Warren Andersen, Vanderbilt University Medical Center, Nashville, TN, United States.